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ABSTRACT
Objective National Spanish studies show that 
prevalence of cervical human papillomavirus (HPV) 
infection in the female population is increasingly 
frequent, with an overall estimate of 14% in women 
aged 18–65 years. The objective of this study is to 
know the prevalence and distribution of HPV types in 
the female population of the Canary Islands prior to 
the introduction of HPV vaccines and to investigate 
the associated clinical and sociodemographic 
factors.
Methods Based on the Primary Health Care database, 
a sample of adult women (aged 18–65 years) of Gran 
Canaria (GC) and Tenerife (TF) stratified into nine age 
groups was carried out between 2002 and 2007. 
Women were contacted by postal letter and telephone 
call and were visited in their primary care centre. A 
clinical- epidemiological survey was completed and 
cervical samples were taken for cytological study and 
HPV detection. HPV prevalence and its 95% CI were 
estimated, and multivariate analyses were performed 
using logistic regression to identify factors associated 
with the infection.
Results 6010 women participated in the study, 3847 
from GC and 2163 from TF. The overall prevalence 
of HPV infection was 13.6% (CI 12.8%–14.5%) and 
11.1% (CI 10.3%–11.9%) for high- risk types. The most 
frequent HPV type was 16 followed by types 51, 53, 
31, 42 and 59. HPV types included in the nonavalent 
vaccine were detected in 54.1% of infected women. 
Factors associated with an increased risk of infection 
were: young ages (18–29 years), the number of sexual 
partners throughout life, not being married, being a 
smoker, and having had previous cervical lesions or 
genital warts.
Conclusions It is confirmed that prevalence of HPV 
infection in the female population of the Canary 
Islands is high, but similar to that of Spain, HPV 16 
being the most frequent genotype. The determinants 
of infection are consistent with those of other 
populations.
INTRODUCTION
Cervical cancer is the fourth most common 
female cancer worldwide and the second 
most frequent among young women aged 
15–44 years, with an estimated 569 847 new 
cases in 2018.1 In Spain, cervical cancer is the 
15th most frequent cancer in women (4th in 
women aged 15–44 years), with an estimated 
1942 new cases in 2018.1 In the Canary Islands 
autonomous community, 356 new cases were 
diagnosed in 2008–2011, with a crude rate of 
10.1 cases per 100 000 women,2 one of the 
highest incidence rates in Spain.3
Human papillomavirus (HPV) is a neces-
sary but not sufficient cause of cervical 
cancer.4 More than 200 HPV genotypes are 
currently known, epidemiologically classified 
into low- oncogenic risk (LR- HPV) and high- 
oncogenic risk (HR- HPV) types.5 HR- HPV 
types include 16 and 18 genotypes, present in 
>70% of cervical cancer cases6 and included 
Strengths and limitations of this study
 ► This is the first prevalence study of human papillo-
mavirus infection in Canary Islands.
 ► The study design is population- based, including the 
main healthcare centres of the participant regions.
 ► Cytological and molecular samples were analysed in 
the same laboratory by the same staff, using highly 
sensitive and partially automated techniques that 
ensured consistency, homogeneity and reproducibil-
ity of diagnostic methods.
 ► Study recruitment time was extensive, from 3 to 6 
years depending on the region.
 ► Characteristics of the study participants could be 
different over time.
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in the three prophylactic HPV vaccines currently commer-
cialised.7 8
No robust estimations of HPV infection prevalence are 
available for the Canary Islands, which hinders compari-
sons with the rest of Spain. Changes in Spanish women’s 
sexual behaviour in the last decades have leads to 
increased HPV infection rates (up to 14% in women aged 
18–65 years, 29% of them in women younger than 25 
years).9 Baseline prevalence estimations of HPV infection 
and the genotype distributions are essential to monitor 
the impact of HPV- vaccination campaigns. Therefore, 
the goal of this study was to estimate the prevalence and 
distribution of HPV types in the female population of the 
Canary Islands before introducing HPV vaccination, as 
well as to study the clinical and sociodemographic factors 
associated with HPV infection.
METHODS
Participants
The study was conducted between 2002 and 2007 on a 
sample of women aged 18–65 years living in any of the 
two most populated Canarian Islands: Gran Canaria and 
Tenerife. Participants were randomly selected from the 
regional Health Administration databases, stratified and 
selected with a probability proportional to the different 
healthcare areas on both islands. Selected women were 
stratified into nine age groups (18–24, 25–29, 30–34, 
35–39, 40–44, 45–49, 50–54, 55–59 and 60–65 years). 
The initial sample included 2276 women. For each age 
group, four reserve groups were obtained to supply the 
absences or refusals to participate. Participants were 
contacted by letter and a subsequent telephone call. A 
visit to the nearest healthcare centre was scheduled. A 
total of 24 345 letters were sent, 15 577 in Gran Canaria 
and 8768 in Tenerife, of which 23.3% agreed to partici-
pate. Women who did not attend the visit were recalled 
by phone to schedule another visit. Subsequently, a group 
of 934 women from Gran Canaria asked to participate in 
the study (volunteers) of which 665 finally attended the 
arranged appointment.
Patient and public involvement
No patients or the public were involved in the design, 
conduct, reporting or dissemination of this study.
Procedures
Participants were asked to fulfil an informed consent form 
and to complete a clinical and epidemiological question-
naire (adapted from International Agency for Research 
on Cancer (IARC) surveys). For cytological collection, the 
wooden Ayre spatula and endocervical brush (cytobrush) 
were used, stained with the Papanicolaou technique and 
the cytological diagnosis was made by a single patholo-
gist according to the criteria of the Bethesda system. 
For the molecular study, a sterile cotton- tipped polysty-
rene swab without culture medium (Deltalab, Spain) was 
used. The obtained cell pellet was subjected to enzymatic 
digestion with stirring for 2 hours at 55°C with proteinase 
K following the inactivation of the process with incuba-
tion for 10 min at 90°C and subsequent centrifugation, 
obtaining DNA from the sample supernatant.
To detect HPV infection, two separated PCR were 
conducted: one using My09/My11 consensus primer 
and the other using Gp5+/Gp6+ consensus primer. DNA 
quality was evaluated by PCR testing for the β-globin 
gene. Samples that were negative for both HPV DNA and 
β-globin were excluded from the final analysis. Samples 
showing positive results for any of the HPV PCR reactions 
or any cytological alteration (atypical squamous cells of 
undetermined significance (ASCUS) or higher) were 
genotyped using the Linear Array HPV Genotyping Test 
(CE- IVD; Roche Diagnostics) or the INNO- LIPA HPV 
Genotyping Extra Amp kit (Immnogenetics (now Fuji-
rebio Europe), Belgium).
Statistical analyses
Descriptive analysis of sociodemographic variables was 
conducted, globally and stratified according to the study 
subpopulation (ie, selected participants from Gran 
Canaria, volunteers from Gran Canaria, selected partic-
ipants from Tenerife). Estimated HPV infection prev-
alence and genotype distribution and corresponding 
95% CIs (Confidence Interval) were calculated as the 
number of HPV- positive women among the total number 
of women tested for each age group, study subpopulation 
and cytological outcome (normal, abnormal). For each 
genotype, estimated prevalences were calculated inde-
pendently including the presence of a given type either 
as a single type or in combination with others (multiple 
infections). Multivariate analysis was conducted using 
basic and adjusted logistic regression models in order to 
assess potential risk factors associated with infections by 
any HPV type and by HR types. Variables were introduced 
one by one into a basic regression model adjusted for age 
group and subpopulation. Variables showing statistically 
significant association (p value <0.05) were kept as adjust-
ment variables in the final model. Statistical analysis was 
carried out with the R software (R Development Core 
Team, 2005, http://www. r- project. org).
RESULTS
Study population
Table 1 shows the characteristics of the study popula-
tion. A total of 6091 women were included: 3212 selected 
from the general Gran Canaria population (52.7%), 665 
volunteers from Gran Canaria (10.9%) and 2214 selected 
from Tenerife (36.3%). Up to 8.4% of participants were 
not born in Spain and came mostly from Latin American 
countries (5.4%); participants’ mean age was 40.7 years; 
64.4% were married at recruitment; 77.5% had been 
pregnant at least once and the mean number of children 
was 2.2. Regarding cytology screening, 53.7% of subjects 
had undergone more than five cytological studies in 
their lives, while 3.5% of them had never undergone 
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Table 1 Characteristics of the study participants (n=6091 
women)
Study sample characteristics N (%)
Distribution by population
  Gran Canaria (general population) 3212 (52.7)
  Gran Canaria (volunteers) 665 (10.9)
  Tenerife 2214 (36.3)
Country of birth
  Spain 5397 (91.6)
  Europe (excluding Spain) 111 (1.9)
  Northern Africa 20 (0.3)
  Sub- Saharian Africa 15 (0.3)
  Latin America and Caribbean 318 (5.4)
  Asia and Oceania 30 (0.5)
  Missing data 200 (−)
Age distribution (years)
  18–24 572 (9.4)
  25–29 663 (10.9)
  30–34 905 (14.9)
  35–39 902 (14.8)
  40–44 793 (13.0)
  45–49 631 (10.4)
  50–54 613 (10.1)
  55–59 502 (8.2)
  60–65 510 (8.4)
Marital status
  Single 1396 (22.9)
  Married/De facto partnership 3919 (64.4)
  Divorced/Separated 573 (9.4)
  Widowed 195 (3.2)
  Missing data 8 (−)
Pregnancies
  No 1343 (22.5)
  Yes 4613 (77.5)
  Missing data 135 (−)
Number of live births*
  0 28 (0.7)
  1 1237 (28.7)
  2 1786 (41.5)
  3 789 (18.3)
  4 277 (6.4)
  ≥5 186 (4.3)
  Missing data 310 (−)
Sexually transmitted disease
  Never 5882 (96.6)
  Ever† 209 (3.4)
  Syphilis‡ 30 (0.5)
Continued
Study sample characteristics N (%)
  Genital herpes‡ 51 (0.8)
  Gonorrhoea‡ 23 (0.4)
  HIV‡ 7 (0.1)
  Genital warts‡ 120 (2.0)
  Chlamydia‡ 30 (0.5)
  Genital ulcer‡ 16 (0.3)
  Others‡ 72 (1.2)
Smoking status
  Never smoked 3443 (56.5)
  Ex- smoker 913 (15.0)
  Current smoker 1735 (28.5)
Previous cervical pap smears
  None 216 (3.5)
  1 493 (8.1)
  2–3 1056 (17.3)
  4–5 772 (12.7)
  >5 3273 (53.7)
  Do not know 281 (4.6)
Previous cervical lesions§
  No 4837 (92.5)
  Yes 385 (7.4)
  Do not know 5 (0.1)
  Missing data 648 (−)
Age at first sexual intercourse (years)
  <15 187 (3.1)
  15–16 828 (13.6)
  17–18 1863 (30.6)
  19–20 1281 (21.0)
  21–25 1421 (23.3)
  >25 442 (7.3)
  Missing data 69 (−)
Lifetime number of sexual partners
  1 3232 (53.9)
  2–3 1571 (26.2)
  4–5 614 (10.2)
  6–10 405 (6.8)
  11–20 126 (2.1)
  >20 49 (0.8)
  Missing data 94 (−)
Contraceptive methods used¶
  Oral contraceptives 4664 (76.6)
  IUD 1133 (18.6)
  Condom 4522 (74.2)
  Rhythm method/Coitus interruptus 3049 (50.1)
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one. Regarding HPV infection- related epidemiological 
factors, 56.5% of subjects were non- smokers and 28.5% 
were smokers at recruitment; 53.9% of subjects had only 
one sexual partner and 47.3% were younger than 19 
years at first sexual intercourse. Demographic character-
istics were slightly different between both islands: educa-
tion level, proportion of smokers and number of sexual 
partners were statistically higher in Tenerife than in Gran 
Canaria. Regarding the subgroup of Gran Canaria volun-
teers, they were younger, with a high level of education, 
more divorced or separated, ex- smokers and with more 
previous cervical pap smears compared with the general 
population of the island (see online supplementary table 
1).
Prevalence of cervical HPV infection
For the prevalence study, 6010 women were included in 
the analysis after excluding 81 women due to poor DNA 
quality in their samples. Prevalence of any- type HPV infec-
tion was 13.6% (95% CI 12.8 to 14.5) while the prevalence 
of HR- HPV infection was 11.1% (95% CI 10.3 to 11.9) 
(table 2). The youngest age group (18–24 years) showed 
the highest prevalence with 26.7% of any- type HPV 
infection (95% CI 23.1 to 30.4). Prevalence progressively 
decreased with increasing age, although the two oldest 
groups (55–65 years) showed a slightly non- significant 
increase compared with the immediately younger group 
(figure 1).
Although volunteers from Gran Canaria showed higher 
prevalence of any- type HPV infection than participants 
from the general population from both Gran Canaria 
(14.5%, 95% CI 11.8 to 17.2 vs 12.7%, 95% CI 11.6 to 
13.9; see online supplementary table 2), the difference 
was not statistically significant. A comparison between 
the two populations from Gran Canaria (general popu-
lation and volunteers) and the population from Tenerife 
showed statistically significant differences in HR- HPV 
infection prevalence (10.6%, 95% CI 9.6 to 11.6 vs 12.1%, 
95% CI 10.7 to 13.4, p=0.002; see online supplementary 
table 2).
Study sample characteristics N (%)
  Injection/Implant 253 (4.2)
  Tube ligation 802 (13.2)
  Vasectomy 549 (9.0)
*Among ever pregnant women (n=4613).
†Includes syphilis, genital herpes, gonorrhoea, HIV (positive test), 
genital warts, chlamydia, genital ulcer, others.
‡Do not add the total of women because a woman could have 
more than one sexually transmitted disease in lifetime.
§Among women with a previous pap smear (n=5875).
¶Do not add the total of women because a woman can use more 
than one contraceptive in lifetime.
Table 1 Continued
Table 2 Prevalence of human papillomavirus (HPV) by age group for any type and for any high- risk (HR) type (n=6010 women)
Age group (years)
Number of tested 
women
Number of HPV- positive 
women
Any HPV prevalence (%, 
95% CI)
Any HR- HPV prevalence* 
(%, 95% CI)
18–24 565 151 26.7 (23.1 to 30.4) 23.9 (20.4 to 27.4)
25–29 655 145 22.1 (19.0 to 25.3) 19.7 (16.6 to 22.7)
30–34 894 161 18.0 (15.5 to 20.5) 15.2 (12.9 to 17.6)
35–39 890 96 10.8 (8.7 to 12.8) 8.0 (6.2 to 9.8)
40–44 783 79 10.1 (8.0 to 12.2) 8.6 (6.6 to 10.5)
45–49 622 59 9.5 (7.2 to 11.8) 7.1 (5.1 to 9.1)
50–54 607 43 7.1 (5.0 to 9.1) 4.9 (3.2 to 6.7)
55–59 495 42 8.5 (6.0 to 10.9) 5.5 (3.5 to 7.5)
60–65 499 44 8.8 (6.3 to 11.3) 5.8 (3.8 to 7.9)
Total 6010 820 13.6 (12.8 to 14.5) 11.1 (10.3 to 11.9)
*HR- HPV types include high- risk types and possibly/probably high- risk types: 16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 53, 66, 67, 68, 69, 
69/71, 70, 73.
Figure 1 Overall prevalence and age- specific prevalence of 
cervical human papillomavirus (HPV) infections by any HPV 
type, any high- risk (HR)- HPV type, HPV types 16/18 and HPV 
types 6/11/16/18/31/33/45/52/58.
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Table 3 shows the distribution of the most frequent 
HPV genotypes. Single- type HPV infection was detected 
in 6% of subjects and multiple infections in 7.2% (corre-
sponding to 43.8% and 52.8% of all HPV- positive women, 
respectively). Among HR- HPV types, type 16 was the 
most frequent one found in 27.8% of positive women 
(including both single and multiple HPV types), followed 
by types 51 (13.7%), 53 (13.3%), 59 (9.9%), 31 (8.5%), 
52 (7.7%) and 18 (6.1%).
Among LR- HPV types, type 42 was the most common 
one (9.3%). In an analysis combining the genotypes 
included in the HPV vaccines, 31.8% of HPV- positive 
women were infected by types 16 and/or 18 while the 
percentage increased to 36.2% when types 6 and/or 11 
were added and to 54.1% when the nine types included 
in the nonavalent vaccine were considered. Figure 1 and 
online supplementary table 3 show the genotype distribu-
tion per age group.
Cytopathological study and cervical HPV infection
The cytological study yielded 317 pathological find-
ings (5.3%) with 69.1% (95% CI 64.0 to 74.2) of HPV 
positivity vs 5693 non- pathological cytologies (94.7%) 
with 10.6% (95% CI 9.8 to 11.4) of HPV positivity (see 
online supplementary table 4), 214 cases of ASCUS were 
detected (3.6%) with 60.7% of HPV positivity, 91 cases 
of low- grade squamous intraepithelial lesions (LSIL) 
(1.5%) with 86.8% of HPV positivity and 12 cases of high- 
grade squamous intraepithelial lesions or worse (HSIL+) 
(0.2%) with 83.3% of HPV positivity. Genotype 16 was 
the most frequently type found in these cytological alter-
ations. Multiple infections were more frequent in women 
with LSIL or HSIL+ as compared with ASCUS (see online 
supplementary table 5).
Cervical HPV infection and associated risk factors
Considering all cases of cervical HPV infection (LR- 
HPV and HR- HPV) and according to the final adjusted 
model, the following statistically significant variables were 
detected in the association with HPV infection: younger 
ages (18–29 years, with a significant lineal trend), not 
married, smokers, more than one sexual partner (statis-
tically significant trend), history of cervical alterations or 
genital warts and practising coitus interruptus (table 4). 
When only cases of HR- HPV cervical infection were 
considered, the same variables showed statistical signifi-
cance except for practising coitus interruptus (see online 
supplementary table 6).
DISCUSSION
Prevalence of cervical HPV infection
The prevalence of cervical HPV infection (LR- HPV and 
HR- HPV) in the whole studied population was 13.6% and 
11.1% for HR- HPV. HPV prevalence in Spain reported in 
other published studies ranges from 2.7% to 17.5%.9–15 
Two published studies were population- based: one by de 
Sanjosé et al10 with a random sample of 973 women from 
the metropolitan area of Barcelona reporting an HPV 
prevalence of 3.4% (95% CI 2.3 to 4.5), which is rather 
lower than ours, and one by García et al15 conducted in 
Castilla y León and reporting 9.6% of HPV prevalence, 
closer to ours. Differences between both studies could be 
explained by changes in sexual behaviour in the Spanish 
population in recent years, with lower age at first sexual 
intercourse and more sexual partners.16
Non population- based studies include CLEOPATRE 
(Prevalence and Genotype Distribution of Human Papil-
lomavirus Infection of the Cervix in Spain),9 a study 
conducted in 17 Autonomous Communities in Spain, 
using the HC2 test and reporting 14.3% (95% CI 13.1 to 
15.5) of HPV prevalence and 12.2% (95% CI 11.1 to 13.4) 
of HR- HPV infection, both results were similar to ours.
Studies conducted in other European countries 
reported varied results, with diverse populations and 
different HPV testing methods. In a review of 18 Euro-
pean studies conducted in 14 countries using the HPV- test 
as first screening (HC2 or PCR) the HR- HPV prevalence, 
standardised by age, ranged from 1.7% in Spain to 12.5% 
in Belgium.17 Bruni et al in a meta- analysis including 1 
million women worldwide with normal cytological find-
ings observed 8.8% global adjusted HPV prevalence in 
Southern Europe, 9% in Western Europe and 10% in 
Northern Europe.18 Studies conducted among women 
from different European screening programmes showed 
HPV prevalences ranging from 6.4% in Germany,19 8.8% 
in Italy,20 13.7% in France,21 15.2% in Belgium,22 19.4% 
in Portugal23 to 26.4% in a population- based study in 
Denmark.24
Prevalence of cervical HPV infection per age group
As expected, the highest HPV prevalence found in our 
study was observed in women aged 18–24 years (26.7%), 
an age group potentially associated with a higher number 
of sexual partners. This finding was also observed in 
previous Spanish and European studies.9 16 17 In our study, 
after this first peak in women <25 years, the prevalence 
declines in older ages, although a slightly, not significant, 
increased was observed in women older than 55 years. 
This second peak in older women was also reported by 
other authors.17 18 20–22 Such a bimodal pattern could be 
due to changes in the sexual behaviour or the reactivation 
of latent viral infections,25 HPV types and their variants 
in such infections, individual susceptibility or regional 
differences in the screening programmes.18
HPV genotypes
HPV 16 was the most prevalent genotype in our popu-
lation, present in 27.8% of positive samples. This prev-
alence was similar to that reported in other studies in 
Spain,10 14 although higher than the 16.9% found in the 
CLEOPATRE study.9 After HPV 16, the most frequent 
types in decreasing order were: HPV 51, 53, 59, 31 and 
52. Our results are similar to most studies conducted in 
Spain9–11 14 and other European countries.19 21–24
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Table 3 Human papillomavirus (HPV) type- specific distribution of the most common types (n=6010 women)
HPV type
Number of HPVpositive 
women (n=820)
HPV prevalenceamong all 
women (n=6010) (%; 95% CI)
HPV prevalence amongpositive 
women (n=820) (%; 95% CI)
Single types 359 6.0 (5.4 to 6.6) 43.8 (40.4 to 47.2)
HR HPV types*
16 75 1.2 (1.0 to 1.5) 9.1 (7.2 to 11.1)
51 34 0.6 (0.4 to 0.8) 4.1 (2.8 to 5.5)
53 28 0.5 (0.3 to 0.6) 3.4 (2.2 to 4.7)
31 16 0.3 (0.1 to 0.4) 2.0 (1.0 to 2.9)
59 14 0.2 (0.1 to 0.4) 1.7 (0.8 to 2.6)
33, 68, 70 11 each 0.2 (0.1 to 0.3)† 1.3 (0.6 to 2.1)†
66 10 0.2 (0.1 to 0.3) 1.2 (0.5 to 2.0)
52 to 58 Nine each 0.1 (0.1 to 0.2)† 1.1 (0.4 to 1.8)†
18 8 0.1 (0.0 to 0.2) 1.0 (0.3 to 1.6)
56 7 0.1 (0.0 to 0.2) 0.9 (0.2 to 1.5)
35 to 39 Five each 0.1 (0.0 to 0.2)† 0.6 (0.1 to 1.1)†
73 4 0.1 (0.0 to 0.1) 0.5 (0.0 to 1.0)
45 3 0.0 (0.0 to 0.1) 0.4 (0.0 to 0.8)
67 2 0.0 (0.0 to 0.1) 0.2 (0.1 to 0.6)
69, 69/71 One each 0.0 (0.0 to 0.0)† 0.1 (0.1 to 0.4)†
LR HPV types‡
42 17 0.3 (0.1 to 0.4) 2.1 (1.1 to 3.0)
84 12 0.2 (0.1 to 0.3) 1.5 (0.6 to 2.3)
62 11 0.2 (0.1 to 0.3) 1.3 (0.6 to 2.1)
61 10 0.2 (0.1 to 0.3) 1.2 (0.5 to 2.0)
6, 55, 81 9 0.1 (0.1 to 0.2) 1.1 (0.4 to 1.8)
89 5 0.1 (0.0 to 0.2) 0.6 (0.1 to 1.1)
54 4 0.1 (0.0 to 0.1) 0.5 (0.0 to 1.0)
11, 43, 72, 83 Two each 0.0 (0.0 to 0.1)† 0.2 (0.1 to 0.6)†
40 1 0.0 (0.0 to 0.0) 0.1 (0.1 to 0.4)
Untyped HPV 28 0.5 (0.3 to 0.6) 3.4 (2.2 to 4.7)
Multiple types 433 7.2 (6.6 to 7.9) 52.8 (49.4 to 56.2)
Number of multiple types
Two types 203 3.4 (2.9 to 3.8) 24.8 (21.8 to 27.7)
Three types 115 1.9 (1.6 to 2.3) 14.0 (11.6 to 16.4)
Four types 73 1.2 (0.9 to 1.5) 8.9 (7.0 to 10.9)
Five or more types 42 0.7 (0.5 to 0.9) 5.1 (3.6 to 6.6)
Most frequent combinations
16 with others 153 2.5 (2.1 to 2.9) 18.7 (16 to 21.3)
53 with others 81 1.3 (1.1 to 1.6) 9.9 (7.8 to 11.9)
51 with others 78 1.3 (1.0 to 1.6) 9.5 (7.5 to 11.5)
59 with others 67 1.1 (0.8 to 1.4) 8.2 (6.3 to 10.0)
42 with others 59 1.0 (0.7 to 1.2) 7.2 (5.4 to 9.0)
31 with others 54 0.9 (0.7 to 1.1) 6.6 (4.9 to 8.3)
52 with others 54 0.9 (0.7 to 1.1) 6.6 (4.9 to 8.3)
66 with others 50 0.8 (0.6 to 1.1) 6.1 (4.5 to 7.7)
54 with others 48 0.8 (0.6 to 1.0) 5.9 (4.2 to 7.5)
Continued
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Many studies have reported the percentage of multiple 
infections9 12 13 15 18–21 23 24 ranging from 8.1% in Spain13 
to 54.3% in Denmark.24 The one from Denmark was 
similar to ours (52.8%), although it included a higher 
percentage of infections by more HPV types. This finding 
could be explained by the use of a HPV detection tech-
nique (hybridisation technology) with a high sensitivity 
for detecting multiple infections.
A total of 31.8% of HPV- positive women (4.3% of the 
total population) were infected by types 16 and/or 18, 
HPV type
Number of HPVpositive 
women (n=820)
HPV prevalenceamong all 
women (n=6010) (%; 95% CI)
HPV prevalence amongpositive 
women (n=820) (%; 95% CI)
62 with others 46 0.8 (0.5 to 1.0) 5.6 (4.0 to 7.2)
89 with others 46 0.8 (0.5 to 1.0) 5.6 (4.0 to 7.2)
61 with others 44 0.7 (0.5 to 0.9) 5.4 (3.8 to 6.9)
56 with others 43 0.7 (0.5 to 0.9) 5.2 (3.7 to 6.8)
18 with others 42 0.7 (0.5 to 0.9) 5.1 (3.6 to 6.6)
58 with others 42 0.7 (0.5 to 0.9) 5.1 (3.6 to 6.6)
84 with others 38 0.6 (0.4 to 0.8) 4.6 (3.2 to 6.1)
39 with others 37 0.6 (0.4 to 0.8) 4.5 (3.1 to 5.9)
45 with others 34 0.6 (0.4 to 0.8) 4.1 (2.8 to 5.5)
68 with others 32 0.5 (0.3 to 0.7) 3.9 (2.6 to 5.2)
81 with others 28 0.5 (0.3 to 0.6) 3.4 (2.2 to 4.7)
six with others 25 0.4 (0.3 to 0.6) 3.0 (1.9 to 4.2)
73 with others 23 0.4 (0.2 to 0.5) 2.8 (1.7 to 3.9)
33 with others 20 0.3 (0.2 to 0.5) 2.4 (1.4 to 3.5)
35 with others 19 0.3 (0.2 to 0.5) 2.3 (1.3 to 3.3)
55 with others 18 0.3 (0.2 to 0.4) 2.2 (1.2 to 3.2)
70 with others 15 0.2 (0.1 to 0.4) 1.8 (0.9 to 2.7)
83 with others 15 0.2 (0.1 to 0.4) 1.8 (0.9 to 2.7)
67 with others 13 0.2 (0.1 to 0.3) 1.6 (0.7 to 2.4)
82 with others 13 0.2 (0.1 to 0.3) 1.6 (0.7 to 2.4)
40 with others 10 0.2 (0.1 to 0.3) 1.2 (0.5 to 2.0)
71 with others 9 0.1 (0.1 to 0.2) 1.1 (0.4 to 1.8)
11 with others 8 0.1 (0.0 to 0.2) 1.0 (0.3 to 1.6)
72 with others 8 0.1 (0.0 to 0.2) 1.0 (0.3 to 1.6)
74 with others 6 0.1 (0.0 to 0.2) 0.7 (0.1 to 1.3)
69 with others 5 0.1 (0.0 to 0.2) 0.6 (0.1 to 1.1)
64 with others 2 0.0 (0.0 to 0.1) 0.2 (0.0 to 0.6)
69/71 with others 2 0.0 (0.0 to 0.1) 0.2 (0.0 to 0.6)
43 with others 0 0.0 (0.0 to 0.0) 0.0 (0.0 to 0.0)
Combinations of vaccine types
6/11§ 43 0.7 (0.5 to 0.9) 5.2 (3.7 to 6.8)
16/18§ 261 4.3 (3.8 to 4.9) 31.8 (28.6 to 35.0)
6/11/16/18§ 297 4.9 (4.4 to 5.5) 36.2 (32.9 to 39.5)
6/11/16/18/31/33/45/52/58§ 444 7.4 (6.7 to 8.0) 54.1 (50.7 to 57.6)
Bold is used to highlight the three main groups of determinations: single, multiple and untyped.
*HR types include high- risk types and possibly/probably high- risk types: 16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 53, 66, 67, 68, 69, 
69/71, 70, 73.
†HPV prevalence for each of the types in the row.
‡LR types include 6, 11, 40, 42, 43, 54, 55, 61, 62, 72, 81, 83, 84, 89.
§One or more of the vaccine types are concerned.
HPV, human papillomavirus; HR, high- risk; LR, low risk.
Table 3 Continued
 on F
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Table 4 Crude and multivariate analyses of the association between cervical human papillomavirus (HPV) infection and 
selected subjects’ characteristics (n=6010 women)
Study sample characteristics
Number of HPV positive 
women / number of HPV 






  Gran Canaria 501/3847 13.0 1.0 (ref) 1.0 (ref)
  Tenerife 319/2163 14.7 1.1 (0.98 to 1.3) 1.0 (0.8 to 1.1)
Country of birth
  Spain 711/5331 13.3 1.0 (ref) 1.0 (ref)
  Europe (excluding Spain) 17/109 15.6 1.3 (0.8 to 2.2) 0.8 (0.5 to 1.5)
  Africa 8/33 24.2 2.7 (1.2 to 6.0) 2.3 (0.99 to 5.4)
  Latin America and Caribbean 51/309 16.5 1.3 (0.9 to 1.8) 1.2 (0.8 to 1.7)
  Asia and Oceania 2/29 6.9 0.6 (0.1 to 2.5) 0.8 (0.2 to 3.5)
  Missing data 31/199 – – –
  Outside Spain (include all 
countries)
78/480 16.3 1.3 (1.0 to 1.7) 1.1 (0.9 to 1.5)
Age distribution (years)
  18–24 151/565 26.7 3.8 (2.6 to 5.4) 2.1 (1.3 to 3.2)
  25–29 145/655 22.1 3.0 (2.1 to 4.2) 1.6 (1.0 to 2.4)
  30–34 161/894 18.0 2.3 (1.6 to 3.4) 1.3 (0.9 to 2.0)
  35–39 96/890 10.8 1.3 (0.9 to 1.8) 0.8 (0.5 to 1.2)
  40–44 79/783 10.1 1.2 (0.8 to 1.7) 0.8 (0.5 to 1.2)
  45–49 59/622 9.5 1.1 (0.7 to 1.7) 0.7 (0.5 to 1.1)
  50–54 43/607 7.1 0.8 (0.5 to 1.2) 0.6 (0.4 to 0.9)
  55–59 42/495 8.5 1.0 (0.6 to 1.5) 0.8 (0.5 to 1.3)
  60–65 44/499 8.8 1.0 (ref) 1.0 (ref)
  P value for trend P<0.001 P<0.001
Level of education
  None / Preschool 40/449 8.9 1.0 (ref) 1.0 (ref)
  Primary 307/2649 11.6 1.0 (0.7 to 1.5) 1.0 (0.7 to 1.4)
  Secondary 241/1477 16.3 1.1 (0.8 to 1.6) 0.9 (0.6 to 1.3)
  University or higher 213/1331 16.0 1.2 (0.8 to 1.7) 0.9 (0.6 to 1.4)
  Others 18/95 18.9 1.2 (0.6 to 2.2) 1.1 (0.5 to 2.0)
  Missing data 1/9 – – –




  Single 329/1379 23.9 2.0 (1.6 to 2.4) 1.5 (1.2 to 1.9)
  Married/de facto partnership 347/3872 9.0 1.0 (ref) 1.0 (ref)
  Divorced/separated 118/560 21.1 3.0 (2.4 to 3.8) 1.8 (1.4 to 2.4)
  Widowed 25/191 13.1 2.1 (1.3 to 3.2) 1.7 (1.0 to 2.6)
  Missing data 1/8 – – –
Number of live births
  No‡ 279/1346 20.7 1.0 (ref) 1.0 (ref)
  1 157/1222 12.8 0.8 (0.6 to 0.9) 0.8 (0.6 to 1.1)
  2 171/1760 9.7 0.7 (0.6 to 0.9) 1.0 (0.7 to 1.3)
  3 80/781 10.2 0.9 (0.6 to 1.2) 1.2 (0.8 to 1.7)
  ≥4 37/458 8.1 0.7 (0.5 to 1.1) 0.9 (0.6 to 1.4)
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which were included in the bivalent vaccine. Regarding 
HPV types included in the quadrivalent vaccine (HPV 6, 
11, 16 and 18), at least one of them was found in 36.2% 
of women (4.9% of the total population). This prevalence 
increased up to 54.1% with the addition of HPV types 
31/33/45/52/58, included in the nonavalent vaccine. 
Such proportions were higher than those reported in 
Denmark24 (27.7%) and in the CLEOPATRE study (22.1% 
in Spain9 and 32.6% in Portugal23). These data illustrate 
the degree of protection offered by HPV vaccines; one out 
of three HPV- infected women would have been protected 
by the bivalent or the quadrivalent vaccine and one out 
of two women would have been protected by the nonava-
lent one. However, the frequency of HPV types 51, 53, 59, 
Study sample characteristics
Number of HPV positive 
women / number of HPV 





  Never smoked 376/3402 11.1 1.0 (ref) 1.0 (ref)
  Ex smoker 126/900 14.0 1.4 (1.1 to 1.7) 1.2 (0.9 to 1.5)
  Current smoker 318/1708 18.6 1.7 (1.5 to 2.1) 1.2 (1.0 to 1.5)
Age at first sexual intercourse (years)
  <15 40/184 21.7 1.5 (0.95 to 2.5) 0.7 (0.4 to 1.2)
  15–16 166/817 20.3 1.4 (0.99 to 2.1) 0.8 (0.5 to 1.2)
  17–18 273/1835 14.9 1.1 (0.8 to 1.6) 0.7 (0.5 to 1.1)
  19–20 143/1266 11.3 0.9 (0.7 to 1.3) 0.7 (0.5 to 1.1)
  21–25 146/1402 10.4 1.0 (0.7 to 1.4) 0.9 (0.6 to 1.3)
  >25 45/437 10.3 1.0 (ref) 1.0 (ref)
  Missing data 7/69 – – –
  P value for trend P=0.001 P=0.3
Lifetime number of sexual partners
  1 214/3189 6.7 1.0 (ref) 1.0 (ref)
  2–3 274/1545 17.7 2.7 (2.2 to 3.3) 2.3 (1.9 to 2.8)
  4–5 141/613 23.0 3.6 (2.8 to 4.6) 2.8 (2.2 to 3.6)
  6–10 119/395 30.1 5.3 (4.0 to 6.9) 3.9 (2.9 to 5.2)
  11–20 41/126 32.5 5.9 (3.9 to 8.8) 4.2 (2.8 to 6.5)
  >20 18/49 36.7 8.1 (4.4 to 14.8) 6.2 (3.3 to 11.5)
  Missing data 13/93 – – –
  P value for trend P<0.001 P<0.001
Use of oral contraceptives
  Never 164/1404 11.7 1.0 (ref) 1.0 (ref)
  Ever 656/4606 14.2 1.2 (1.0 to 1.5) 1.1 (0.9 to 1.4)
Rhythm method/coitus interruptus
  Never 381/2998 12.7 1.0 (ref) 1.0 (ref)
  Ever 439/3012 14.6 1.3 (1.1 to 1.5) 1.2 (1.0 to 1.4)
Previous cervical lesions
  No 645/4986 12.9 1.0 (ref) 1.0 (ref)
  Yes 84/378 22.2 2.1 (1.6 to 2.7) 1.6 (1.2 to 2.1)
  Missing data§ 91/646 – – –
Genital warts
  Never 783/5894 13.3 1.0 (ref) 1.0 (ref)
  Ever 37/116 31.9 2.8 (1.8 to 4.2) 1.7 (1.1 to 2.6)
Bold is used to highlight the three main groups of determinations: single, multiple and untyped.
*Basic model: adjusted for age group (18–24, 25–34, 35–44, 45–54, 55–65 years) and population (Gran Canaria, Tenerife).
†Adjusted model: adjusted for age group, population, level of education, marital status, smoking habits, lifetime number of sexual partners, previous 
cervical lesions, ever use of rhythm method and ever had genital warts.
‡Includes women who were pregnant but had 0 live births.
§Includes ‘Do not know’ in the ‘Missing data’ category.
POR, prevalence odds ratio.
Table 4 Continued
 on F
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frequently found in our population, indicate the need to 
continue the cytological screening population.
Cytopathological study and cervical HPV infection
Cytological alterations found in our study (5.3%) were 
similar to those observed in other studies, both in 
Spain9 10 14 and Europe,19 20 22–24 ranging between 1.6% 
and 7%. The HPV prevalence increased with lesion 
severity (60.7% in women with ASCUS; 86.8% in women 
with LSIL and 83.3% in women with HSIL+). This finding 
was in agreement with other published studies.9 10 12 19 21–24 
The HPV prevalence in normal cytologies was 10.6%, 
similar to that reported by Bruni et al18 in our geograph-
ical area (8.8%), although lower than that reported in 
most studies.9 21–24
Risk factors and cervical HPV infection
Age consistently appears as a risk factor for HPV infec-
tion, both in our study and other published ones,14 20 26 27 
directly associated with younger women’s sexual behaviour 
as compared with older ones.
Number of sexual partners in life extensively 
appears10 11 14 26–28 as a risk factor for HPV infection and 
was the factor with the largest impact in our study. As in 
our study, most authors failed to find a relationship with 
age at first intercourse.10 26 27 This later parameter seems 
to influence number of sexual partners but does not seem 
to be an independent risk factor for HPV infection.
In our analysis, not being married (divorced, widow or 
single) was a statistically significant risk factor for HPV 
infection, as was also reported in other studies.10 20 26 This 
finding could be explained by the sexual behaviour of 
not married women, who may probably have more sexual 
partners.
Coitus interruptus was the only contraception- related 
practice found to be associated with higher risk of any- 
type HPV infection, both in the basic and the adjusted 
models, although such an association was not found 
for HR- HPV types. This factor might possibly be linked 
to younger groups, where other risk increasing factors 
coexist.
Smoking was a risk factor for HPV infection in our 
population, in accordance with data reported by other 
authors,26 27 29 although not by others.10 Quitting smoking 
has been considered to potentially revert infection risk.29 
In order to explain for the relationship between smoking 
and increased risk of HPV infection, it has been postu-
lated that tobacco and its metabolites may alter the 
immune system of the cervical epithelium, thus reducing 
the number of CD4 lymphocytes and Langerhans cells29 
and impairing the activity of natural killer cells.
The presence of genital warts and previous cervical 
alterations was associated with higher risk in our popula-
tion, as well as in other studies,26 which is not surprising 
since both events are directly related.
Country of origin especially African ones, appeared as a 
risk factor for HPV infection in our basic model, although 
not in our adjusted model. Earlier published Spanish 
studies showed higher HPV infection risk in women born 
out of Spain,10 11 26 probably due to differences in the 
sexual behaviour of men and women.
Regarding parity and HPV infection risk, similar to other 
authors,20 we found some protective effect in women with 
one or two births in our basic model for any- type HPV, 
although not for the adjusted model or for HR- HPV types, 
a finding also reported by some authors.10 26 27 In a meta- 
analysis published by the IARC,30 a slight risk increase in 
nulliparous women (younger and more sexually active) 
as compared with women who have been pregnant was 
described.
The relationship between taking oral contraceptives 
(OC) and the risk of HPV infection is controversial. In our 
population, a slightly increased risk was found for women 
taking OC in the basic model though not in the adjusted 
model, a finding also described in other studies.10 20 26 27 30
Infection by other sexually transmitted diseases anal-
ysed in our population increased the risk in the basic 
model but not in the adjusted model (data not shown), 
consistent with other published studies.26 27
Some authors have reported no association between 
using condoms and increased risk of HPV infec-
tion14 20 27 28; some even reported some protective effect.26 
In our study, like with other contraceptive methods we 
failed to find an association with HPV infection (data 
not shown). The evidence is controversial regarding the 
association between HPV infection and level of educa-
tion.26 27 31
Strengths and weaknesses
One of the main strengths of our study was our population- 
based design, which covered the main healthcare centres 
on the islands and recruited potential participants from 
an official source, ensuring a random sample. Addition-
ally, the fact that all cytological and molecular studies 
were conducted in the same laboratory, by the same tech-
nical and medical staff, using highly sensitive and partially 
automated analytic systems ensured consistency, homoge-
neity and reproducibility of diagnostic methods.
The prolonged recruitment time was a weakness of this 
study. Three years were needed for Tenerife and 6 years 
for Gran Canaria, although 2 years had been originally 
planned. Potential variations over time could have influ-
enced the sociodemographic characteristics of the popu-
lation. Thus, the characteristics of participants recruited 
at the beginning of the recruitment period could have 
been different from those of women recruited by the end.
CONCLUSIONS
This study provides population- based references for 
the prevalence of HPV infection in the Canary Islands, 
which enables future assessment of the impact of HPV 
vaccination campaigns. The prevalence of HPV infection 
in the female population of Gran Canaria and Tenerife 
was high, although similar to that of previous studies 
conducted in Spain, with genotype HPV 16 being the 
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most frequent one. These results support the potential 
benefits of HPV vaccines in terms of reducing infection 
as well as the consequent development of HPV- related 
lesions, including cancer.
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